

COMPANY ANNOUNCEMENT

KarmelSonix Receives Further Regulatory Clearance for its Products and Quality System

HIGHLIGHTS

- The PulmoTrack® has received clearance by the Israeli Ministry of Health for sale in Israel
- KarmelSonix (Israel) Ltd Quality System has received approval from the Canadian Standards Authority
- Regulatory process continues in S. Korea (KFDA), China (SFDA), Australia (TGA for WheezoMeter) and Taiwan for Product Registration

20th April 2009: The Directors of KarmelSonix Ltd (KSX or the Company) are pleased to announce that KarmelSonix’ PulmoTrack® Technology has received clearance by AMAR, the Israeli Ministry of Health regulatory authorities. This approval will facilitate the onset of sales of the PulmoTrack® in Israel and will also streamline the process for having clinical studies approved in Israel. This regulatory approval follows the approvals of the PulmoTrack® received previously by the FDA, TGA and CE and the Wheezometer by European, CE.

In late March 2009 KarmelSonix (Israel) Ltd was audited by DQS Group Certification Services. The Company complied with the requirements for medical devices quality management systems according to ISO 13485 under the Canadian Medical Devices Conformity Assessment System (CMDCAS) based on the Health Canada guidance documents GD 207 (November 2007) and GD 210 (January 2007). This is a prerequisite for clearing the PulmoTrack and the WheezoMeter for sale in the Canadian market.

In addition, the regulatory processes for obtaining the necessary approvals in China, Taiwan and Korea, where appointed Territorial distributors are continuing to work with local consultants and translators to get approval for our devices, is continuing.

The Directors also wish to notify that Prof. Nathan Intrator has advised the Board that he wishes to take 3 months leave from KSI in order to pursue certain academic activities at Tel-Aviv University. Prof. Intrator will continue to serve the Company as a Director and Consultant. In the interim Prof. Noam Gavriely has agreed to serve as General Manager of KSI and will continue to work closely with Mr. Amir Ohad (company CFO) on the business development aspects of the company, as well as with the rest of the senior management team.

For additional information please contact:

Mr. Peter Marks, Chairman	+61 (0)3 9824 8166	Peter@karmelsonix.com
Prof. Nathan Intrator, Director	+972 544 650 365	Nathan@karmelsonix.com
Prof. Noam Gavriely, Director	+972 544 661 337	Noam@karmelsonix.com
Dr Henry Pinski, Director	+ 61 400 313 732	henry@karmelsonix.com



“Wheeze Rate – A New Paradigm in Asthma Management”

KarmelSonix Ltd. focuses on supplying innovative non-invasive acoustic tools for disease management of asthma and related pulmonary disorders. Asthma affects 6-16% of the population in developed countries with a cost exceeding \$US15 billion in the US alone.

Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all ages, including the very young, very old and others who cannot perform currently available tests. The technology that comes from extensive R&D and clinical validation in the US, Israel and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during sleep. The company is focused on early commercialization of its products with special emphasis on the European and North American markets.

“Wheeze Rate – A New Paradigm in Asthma Management”

KarmelSonix Ltd. (KSX)
Suite 2, 1233 High Street
Armadale VIC 3143 Australia

PulmoSonix Pty, Ltd.
336A Glenhuntly Road
Elsternwick VIC 3185 Australia

KarmelSonix (Israel) Ltd.
16 Palyam Avenue
Haifa, Israel